Comparison

Semax vs NA-Selank Amidate

Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research

Semax

Also: SEMAX, Heptapeptide SEMAX

Clinical Trials

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed in Russia in the 1980s as an analog of the ACTH(4-10) fragment, with a Pro-Gly-Pro tail added to resist breakdown. It is researched and used as a neuroprotective and nootropic agent, typically intranasally, and keeps the cognitive and neurotrophic effects of the ACTH fragment without the parent hormone's cortisol-raising activity. It is used clinically and registered in Russia (including for ischemic stroke and cognitive disorders) but is not approved by the FDA or EMA, and Western evidence is limited.

CognitiveHuman Trials
NA-Selank Amidate

Also: N-Acetyl Selank Amidate, NA-Selank

Clinical Trials

NA-Selank Amidate is a chemically stabilized version of Selank, a Russian anxiolytic peptide derived from the immune fragment tuftsin. The acetyl group on one end and the amide on the other are there to slow enzymatic breakdown, which is a real and sensible modification. What has not been established is whether that translates into a meaningfully better result than plain Selank in humans.

CognitiveHuman Trials

Key Comparison Insights

  • Both peptides belong to the Cognitive category, suggesting similar primary applications.

Detailed Comparison

AttributeSemaxNA-Selank Amidate
CategoryCognitiveCognitive
FDA StatusNot FDA ApprovedNot FDA Approved
Clinical Status
Pre
I
II
III
IV
FDA
Pre
I
II
III
IV
FDA
Mechanism of ActionSemax is derived from ACTH(4-10) but, unlike ACTH, does not stimulate the adrenal or cortisol axis; its main documented action is upregulating brain-derived neurotrophic factor (BDNF) and its receptor TrkB, especially in the hippocampus. In rats, a single dose increases BDNF protein and mRNA and raises TrkB phosphorylation, activating growth and survival pathways (such as MAPK/ERK and PI3K/Akt) that support neuron health and plasticity. It also modulates dopamine and serotonin signaling and influences genes tied to the immune and vascular response after brain ischemia. The combined effect in animal models is neuroprotection against insults like reduced blood flow and oxidative stress, plus enhanced learning and memory. The Pro-Gly-Pro extension makes it more stable than the bare ACTH(4-10) sequence, which is partly why it stays active intranasally.Selank is a synthetic analog of tuftsin, a naturally occurring immunomodulatory peptide fragment. Its reported mechanism has two strands. The first is modulation of GABAergic signalling, which is the basis of its anxiolytic reputation, achieved without the sedation, tolerance or dependence associated with benzodiazepines. The second is an effect on the balance of monoamines and on BDNF expression, which is where the cognitive and mood claims come from. It also retains some of tuftsin's immunomodulatory activity, including effects on interleukin expression. The N-acetylation and C-terminal amidation in this version block the exopeptidases that would otherwise clip the peptide quickly, extending how long it survives after administration. That is a pharmacokinetic change, not a new mechanism.
Common Dosing
200-600 mcg intranasal daily
1-3x daily, intranasal
250-500 mcg daily (intranasal)
Once or twice daily
AdministrationIntranasal spray (most common)Intranasal is the standard route. Subcutaneous is reported but less common.
Typical Duration10-30 days typicalCommunity protocols commonly report 2-4 weeks, though Selank's clinical use does not indicate a dependence risk requiring cycling
Best Time to TakeMorning or early afternoonMorning or split across the day
Possible Side Effects
May vary by individual
  • Nasal irritation (common)
  • Headache
  • Insomnia
  • Increased anxiety (paradoxical in some)
  • Nausea
  • +2 more
  • Generally reported as well tolerated
  • Nasal irritation or dryness with intranasal use
  • Mild fatigue or flat affect at higher doses
  • Headache
  • No dependence or withdrawal syndrome reported, unlike benzodiazepines
  • +1 more
Research SummaryThe mechanistic core is well documented preclinically: Dolotov et al. (2006, Brain Research) showed a single intranasal Semax dose raised hippocampal BDNF protein, TrkB phosphorylation, and BDNF and TrkB mRNA in rats, alongside improved learned behavior. Additional rat work shows neuroprotection and changes in immune- and vascular-related gene expression after experimental stroke. Human clinical use is real but the published trials are mostly Russian-language, small, and frequently non-randomized or open-label: studies in acute ischemic-stroke patients reported faster recovery of neurological function, and a 2018 study reported increased plasma BDNF with improvements on disability and motor scales. These results are promising but methodologically weaker than Western regulatory-grade trials and have not been replicated in large independent Western studies. Honest summary: solid animal mechanistic data and decades of Russian clinical use, but the human cognitive and stroke claims rest on small, mostly non-randomized studies and are not validated by FDA or EMA-grade trials.Selank itself has a real research base, almost all of it Russian, including clinical work in generalised anxiety disorder where it performed comparably to benzodiazepines without the sedation and withdrawal profile, plus animal work supporting the BDNF and monoamine effects. That literature is genuine but it is largely published in Russian journals, has not been replicated in large Western trials, and has not been through FDA or EMA assessment. The amidate variant specifically has essentially no independent published pharmacology. The stability argument is chemically sound and is the same modification used across many research peptides, but nobody has published a human comparison showing it outperforms standard Selank at equivalent doses. Treat the parent compound's evidence as real but geographically narrow, and the variant's advantage as plausible rather than demonstrated.

Frequently Asked Questions: Semax vs NA-Selank Amidate

What is the difference between Semax and NA-Selank Amidate?

Semax is a cognitive peptide that semax is a synthetic heptapeptide (met-glu-his-phe-pro-gly-pro) developed in russia in the 1980s as an analog of the acth(4-10) fragment, with a pro-gly-pro tail added to resist breakdown. it is researched and used as a neuroprotective and nootropic agent, typically intranasally, and keeps the cognitive and neurotrophic effects of the acth fragment without the parent hormone's cortisol-raising activity. it is used clinically and registered in russia (including for ischemic stroke and cognitive disorders) but is not approved by the fda or ema, and western evidence is limited. NA-Selank Amidate is a cognitive peptide that na-selank amidate is a chemically stabilized version of selank, a russian anxiolytic peptide derived from the immune fragment tuftsin. the acetyl group on one end and the amide on the other are there to slow enzymatic breakdown, which is a real and sensible modification. what has not been established is whether that translates into a meaningfully better result than plain selank in humans. The main differences lie in their mechanisms of action and clinical applications.

Which is better, Semax or NA-Selank Amidate?

Neither is universally "better" - the choice depends on your specific goals. Semax is typically used for cognitive purposes, while NA-Selank Amidate is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.

Can Semax and NA-Selank Amidate be used together?

Some peptide protocols combine multiple compounds for synergistic effects. However, using Semax and NA-Selank Amidate together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.

Related Comparisons

View Full Peptide Profiles